New study tracks Real-Life use of kidney drugs in IgA nephropathy
NCT ID NCT07481084
First seen Apr 02, 2026 · Last updated May 08, 2026 · Updated 5 times
Summary
This study will follow about 80 adults with IgA nephropathy (a kidney disease) who are starting treatment with iptacopan or atrasentan. Researchers want to see how these drugs work in everyday medical practice, not in a controlled experiment. Each person will be observed for 24 months to collect information on their health, treatments, and outcomes. The goal is to better understand patient profiles and treatment patterns, and to contribute to a larger global analysis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.